James C. Foster was named Chief Executive Officer of Charles River Laboratories International, Inc., effective May 5, 2026. As of November 14, 2026, Charles River Laboratories International, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from January 9, 2026 to February 18, 2026, naming 1 appointment (Form 8-K, January 9, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Charles River Laboratories International, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Charles River Laboratories International, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-01-09 to 2026-02-18. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Charles River Laboratories International, Inc. files it.
Also on the record for Charles River Laboratories International, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 10, 2026 | Stake report, Schedule 13G/A, by Invesco Ltd. | 3.9% of the class | 5%+ stakes | Source |
| November 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 12.4% of the class | 5%+ stakes | Source |
| September 8, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 10.2% of the class | 5%+ stakes | Source |
| August 13, 2026 | Stake report, Schedule 13G, by Invesco Ltd. | 6.2% of the class | 5%+ stakes | Source |
| August 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 8.8% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G, by FMR LLC | 7% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G/A, by Invesco Ltd. | 4.9% of the class | 5%+ stakes | Source |
| April 29, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 7.38% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 12, 2026 | Stake report, Schedule 13G, by Invesco Ltd. | 5.5% of the class | 5%+ stakes | Source |
| February 10, 2026 | Stake report, Schedule 13G/A, by Wellington Management Group LLP | 3.6% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by NOMURA HOLDINGS INC | 1.6% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Charles River Laboratories International, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Charles River Laboratories International, Inc. and the records around it.
Charles River Laboratories International, Inc. elsewhere on the record
Companies that share a holder
- NOMURA HOLDINGS INC also filed stake reports on 21 other companies: DESTINATION XL GROUP, INC. (Aug 2026), Integer Holdings Corp (Aug 2026), Torrid Holdings Inc. (Aug 2026)
- Invesco Ltd. also filed stake reports on 93 other companies: Alignment Healthcare Inc (Nov 2026), ArcBest Corp (Nov 2026), Canaan Inc (Nov 2026)
- Wellington Management Group LLP also filed stake reports on 240 other companies: Hub Group, Inc. (Oct 2026), Latham Group, Inc. (Oct 2026), Redwood Trust, Inc. (Oct 2026)
Watch Charles River Laboratories International, Inc.
Get an email when Charles River Laboratories International, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Charles River Laboratories International, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Charles River Laboratories International, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Charles River Laboratories International, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 14 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-02-18 | Reported | not named in the filing | 8-K, 2026-02-18 | ||
| 2026-01-09 | In | Chief Executive Officer | 2026-05-05 | 8-K, 2026-01-09 |
Who leads Charles River Laboratories International, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Executive Officer: James C. Foster, appointed, effective 2026-05-05 (filed 2026-01-09).
New leaders reset buying decisions — get the Full Report on Charles River Laboratories International, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Executive Officer at Charles River Laboratories International, Inc., with the record behind each one.
Find candidates like Chief Executive Officer at Charles River Laboratories International, Inc.Every change, in the filing's words
Reported
On February 18, 2026, the Company announced the appointment of Glenn Coleman as its Corporate Executive Vice President and Chief Financial Officer.
- Mr. Coleman will join the company with a tentative start date of April 6, 2026.
- Mr. Coleman, 58, will join Charles River with over 30 years of strong financial and operational management experience, including more than a decade of senior leadership roles in the healthcare sector.
- Most recently since 2024, Mr. Coleman has been serving as Chief Financial Officer and Chief Administrative Officer of Premier, Inc., a $1-billion healthcare services business.
- Prior to this role, he was the CFO of two public companies, DENTSPLY SIRONA Inc. and Integra Life Sciences Holdings Corporation.
- Mr. Coleman served as Executive Vice President and CFO at DENSTPLY from 2022 to 2024.
- Prior to DENTSPLY, he held operational and financial leadership positions at Integra Life Sciences from 2014 to 2022, including as Executive Vice President and Chief Operating Officer from 2019 to 2022, and previously as CFO and Corporate Vice President, International.
- In addition to overseeing its Finance department as CFO, as Integra's COO, Mr. Coleman led operations and most of its talent force, including clinical, research and development, manufacturing, and quality functions while also leading the international team.
Appointed: James C. Foster, Chief Executive Officer, effective 2026-05-05
Mr. James C. Foster, our current Chairman of the Board, President and Chief Executive Officer, intends to step down as Chief Executive Officer and Chairman of the Board, and Ms. Birgit Girshick, our Chief Operating Officer, will be appointed as our Chief Executive Officer, each effective as of May 5, 2026 (the "Transition Date").
- Chief Executive Officer Transition On January 8, 2026, the Board of Directors (the "Board") of Charles River Laboratories International, Inc. (the "Company") announced a leadership transition plan.
- Following the Transition Date, it is expected that Mr. Foster will remain a non-executive director of the Board.
- Dr. Martin Mackay, current Lead Independent Director, is expected to become Chair of the Board, effective as of the Transition Date.
- In addition, Ms. Girshick has been nominated by the Board to become a director of the Company effective at the 2026 Annual Meeting of Shareholders, which is expected to take place on the Transition Date.
- Relatedly, the Board has approved increasing the size of the Board from 11 to 12, effective as of the Transition Date.
- In connection with the increase in the size of the Board, each of Elliott Investment Management L.P, Elliott Associates, L.P., and Elliott International, L.P., provided a limited consent under the Cooperation Agreement with the Company, dated May 6, 2025, permitting the increase for Ms. Girshick to join the Board as contemplated.
- Terms and Conditions of Ms. Girshick's Employment In connection with the announcement of Ms. Girshick's appointment as our Chief Executive Officer, the Company entered into a letter agreement with Ms. Girshick.
Tools for this story
Each opens in a new tab, filled in for Charles River Laboratories International, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
